China National Accord Medicines Corp Ltd (200028) — Capital Reinvestment Ratio
China National Accord Medicines Corp Ltd (200028) has a Capital Reinvestment Ratio of 0.03x as of June 2025, meaning it reinvests 0% of its operating cash flow (HK$1.83 Billion) in capital expenditures (HK$50.09 Million). Check 200028 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
China National Accord Medicines Corp Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks China National Accord Medicines Corp Ltd's Capital Reinvestment Ratio across 27 annual periods. For the full cash flow conversion analysis, see how efficiently does China National Accord Medicines Corp Ltd generate cash.
Annual Capital Reinvestment Ratio for China National Accord Medicines Corp Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for China National Accord Medicines Corp Ltd from 1998 to 2025. See cash generation quality of China National Accord Medicines Corp Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (HKD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | HK$1.64 Billion | HK$217.35 Million | ▲ +53.5% |
| 2024 | 0.09x | HK$3.27 Billion | HK$282.70 Million | ▼ -21.2% |
| 2023 | 0.11x | HK$2.94 Billion | HK$322.21 Million | ▼ -12.8% |
| 2022 | 0.13x | HK$2.56 Billion | HK$322.19 Million | ▼ -43.8% |
| 2021 | 0.22x | HK$1.66 Billion | HK$370.43 Million | ▲ +14.5% |
| 2020 | 0.20x | HK$1.50 Billion | HK$293.83 Million | ▲ +59.5% |
| 2019 | 0.12x | HK$2.00 Billion | HK$245.17 Million | ▼ -36.6% |
| 2018 | 0.19x | HK$1.32 Billion | HK$255.48 Million | ▲ +21.5% |
| 2017 | 0.16x | HK$1.29 Billion | HK$204.35 Million | ▼ -11.9% |
| 2016 | 0.18x | HK$1.47 Billion | HK$265.89 Million | ▼ -0.6% |
| 2015 | 0.18x | HK$1.05 Billion | HK$190.36 Million | ▼ -43.9% |
| 2013 | 0.32x | HK$465.03 Million | HK$150.50 Million | ▼ -45.8% |
| 2012 | 0.60x | HK$323.96 Million | HK$193.57 Million | ▼ -31.7% |
| 2011 | 0.88x | HK$227.32 Million | HK$198.97 Million | ▲ +110.6% |
| 2010 | 0.42x | HK$428.16 Million | HK$177.99 Million | ▲ +9.4% |
| 2009 | 0.38x | HK$270.85 Million | HK$102.94 Million | ▲ +10.3% |
| 2008 | 0.34x | HK$246.58 Million | HK$84.98 Million | ▼ -57.7% |
| 2007 | 0.81x | HK$87.70 Million | HK$71.41 Million | ▲ +25.2% |
| 2006 | 0.65x | HK$181.73 Million | HK$118.22 Million | ▲ +90.5% |
| 2005 | 0.34x | HK$148.28 Million | HK$50.62 Million | ▲ +213.6% |
| 2004 | 0.11x | HK$130.30 Million | HK$14.18 Million | ▼ -82.1% |
| 2003 | 0.61x | HK$81.22 Million | HK$49.36 Million | ▼ -35.0% |
| 2002 | 0.94x | HK$28.76 Million | HK$26.90 Million | ▲ +85.3% |
| 2001 | 0.50x | HK$71.16 Million | HK$35.91 Million | ▼ -79.5% |
| 2000 | 2.47x | HK$8.52 Million | HK$21.01 Million | ▲ +104.6% |
| 1999 | 1.21x | HK$22.84 Million | HK$27.54 Million | ▼ -39.5% |
| 1998 | 1.99x | HK$5.21 Million | HK$10.38 Million | — |